10-K.Info (Beta Test)
Courtesy of Short Sands, LLC
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

ABBOTT LABORATORIES

Ticker: ABT   Fiscal Year: 2016

Consolidated Statement of Earnings

Period Ending Dec 31, 2016 10-K (Filed: Feb 17, 2017)

(In Millions)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2016Dec 31, 2015Dec 31, 2014
Net Sales
$
20,853
20,40520,247
Cost of products sold, excluding amortization of intangible assets9,0248,7479,218
Amortization of intangible assets550601555
Research and development1,4221,4051,345
Selling, general and administrative6,6726,7856,530
Total Operating Cost and Expenses17,66817,53817,648
 
Operating Earnings3,1852,8672,599
 
Interest expense431163150
Interest income(99)(105)(77)
Net loss on extinguishment of debt18
Net foreign exchange (gain) loss495(93)(24)
Other (income) expense, net945(281)14
Earnings from Continuing Operations Before Taxes1,4133,1832,518
 
Taxes on Earnings from Continuing Operations350577797
Earnings from Continuing Operations1,0632,6061,721
 
Earnings from Discontinued Operations, net of taxes32165563
Gain on sale of Discontinued Operations, net of taxes161,752
Net Earnings from Discontinued Operations, net of taxes3371,817563
 
Net Earnings1,4004,4232,284
 
Basic Earnings Per Common Share --
Continuing Operations (in dollars per share)0.711.731.13
Discontinued Operations (in dollars per share)0.231.210.37
Net Earnings (in dollars per share)0.942.941.50
 
Diluted Earnings Per Common Share --
Continuing Operations (in dollars per share)0.711.721.12
Discontinued Operations (in dollars per share)0.231.200.37
Net Earnings (in dollars per share)0.942.921.49
 
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)1,4771,4961,516
Dilutive Common Stock Options (in shares)61011
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)1,4831,5061,527
 
Outstanding Common Stock Options Having No Dilutive Effect (in shares)511
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

ABBOTT LABORATORIES

Ticker: ABT   Fiscal Year: 2016

Consolidated Statement of Comprehensive Income

Period Ending Dec 31, 2016 10-K (Filed: Feb 17, 2017)

(In Millions, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2016Dec 31, 2015Dec 31, 2014
Net Earnings (Loss)
$
1,400
4,4232,284
Foreign currency translation (loss) adjustments(130)(2,013)(2,206)
Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $(125) in 2016, $101 in 2015 and $(459) in 2014(326)252(917)
Unrealized gains (losses) on marketable equity securities, net of taxes of $(28) in 2016, $104 in 2015 and $(7) in 2014(134)64(12)
Net (losses) gains on derivative instruments designated as cash flow hedges, net of taxes of $(4) in 2016, $(9) in 2015 and $24 in 2014(15)(35)94
Other Comprehensive (Loss) Income(605)(1,732)(3,041)
 
Comprehensive Income (Loss)7952,691(757)
 
Supplemental Accumulated Other Comprehensive Income Information, net of tax as of December 31:
Cumulative foreign currency translation (loss) adjustments(4,959)(4,829)(2,924)
Net actuarial (losses) and prior service (cost) and credits(2,284)(1,958)(2,229)
Cumulative unrealized (losses) gains on marketable equity securities(69)651
Cumulative gains on derivative instruments designated as cash flow hedges496499
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

ABBOTT LABORATORIES

Ticker: ABT   Fiscal Year: 2016

Consolidated Statement of Cash Flows

Period Ending Dec 31, 2016 10-K (Filed: Feb 17, 2017)

(In Millions, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2016Dec 31, 2015Dec 31, 2014
Cash Flow From (Used in) Operating Activities:
Net earnings
$
1,400
4,4232,284
Adjustments to reconcile earnings to net cash from operating activities -
Depreciation803871918
Amortization of intangible assets550601630
Share-based compensation310292246
Impact of currency devaluation480
Investing and financing (gains) losses, net86(18)69
Amortization of bridge financing fees165
Net loss on extinguishment of debt18
Gain on sale of discontinued operations(25)(2,840)
Mylan N.V. equity investment adjustment947
Gain on sale of Mylan N.V. shares(207)
Trade receivables(177)(171)(195)
Inventories(98)(257)(297)
Prepaid expenses and other assets1135730
Trade accounts payable and other liabilities(652)(742)(225)
Income taxes(699)957197
Net Cash From Operating Activities3,2032,9663,675
 
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment(1,121)(1,110)(1,077)
Acquisitions of businesses and technologies, net of cash acquired(80)(235)(3,317)
Proceeds from business dispositions252305
Proceeds from the sale of Mylan N.V. shares2,290
Purchases of investment securities(2,823)(4,933)(1,507)
Proceeds from sales of investment securities3,7094,1125,624
Other425270
Net Cash From (Used in) Investing Activities(248)406(202)
 
Cash Flow From (Used in) Financing Activities:
Proceeds from issuance of (repayments of) short-term debt and other(1,767)(1,281)1,343
Proceeds from issuance of long-term debt and debt with maturities over 3 months14,9342,485
Repayments of long-term debt and debt with maturities over 3 months(12)(57)(577)
Payment of bridge financing fees(170)
Acquisition and contingent consideration payments related to business acquisitions(25)(17)(400)
Purchases of common shares(522)(2,237)(2,195)
Proceeds from stock options exercised, including income tax benefit248314429
Dividends paid(1,539)(1,443)(1,342)
Net Cash From (Used in) Financing Activities11,147(2,236)(2,742)
 
Effect of exchange rate changes on cash and cash equivalents(483)(198)(143)
Net (Decrease) Increase in Cash and Cash Equivalents13,619938588
 
Cash and Cash Equivalents, Beginning of Year5,0014,063
Cash and Cash Equivalents, End of Year18,6205,0014,063
 
Supplemental Cash Flow Information:
Income taxes paid620631448
Interest paid181166146
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

ABBOTT LABORATORIES

Ticker: ABT   Fiscal Year: 2016

Consolidated Balance Sheet

Period Ending Dec 31, 2016 10-K (Filed: Feb 17, 2017)

(In Millions, except shares in actual)
 As ofAs of
 Dec 31, 2016Dec 31, 2015
Assets
Current Assets:
Cash and cash equivalents
$
18,620
5,001
Investments, primarily bank time deposits and U.S. treasury bills1551,124
Trade receivables, less allowances of - 2016: $250; 2015: $3373,2483,418
Inventories:
Finished products1,6241,744
Work in process294316
Materials516539
Total inventories2,4342,599
 
Other prepaid expenses and receivables1,8061,908
Current assets held for disposition513105
Total Current Assets26,77614,155
 
Long-term Investments2,9474,041
Property and Equipment, at Cost:
Land408432
Buildings2,6022,769
Equipment8,3948,254
Construction in progress962928
Property and Equipment, at cost12,36612,383
 
Less: accumulated depreciation and amortization6,6616,653
Net Property and Equipment5,7055,730
 
Intangible Assets, net of amortization4,5395,562
Goodwill7,6839,638
Deferred Income Taxes and Other Assets2,2632,119
Non-current Assets Held for Disposition2,7532
Total Assets52,66641,247
 
Liabilities and Shareholders' Investment
Current Liabilities:
Short-term borrowings1,3223,127
Trade accounts payable1,1781,081
Salaries, wages and commissions752746
Other accrued liabilities2,5813,043
Dividends payable391383
Income taxes payable188430
Current portion of long-term debt33
Current liabilities held for disposition245373
Total Current Liabilities6,6609,186
 
Long-term Debt20,6815,871
Post-employment Obligations and other long-term liabilities4,5494,864
Non-current liabilities held for disposition59
Commitments and Contingencies  
Shareholders' Investment:
Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued  
Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2016: 1,707,475,455; 2015: 1,702,017,39013,02712,734
Common shares held in treasury, at cost - Shares: 2016: 234,606,250; 2015: 229,352,338(10,791)(10,622)
Earnings employed in the business25,56525,757
Accumulated other comprehensive income (loss)(7,263)(6,658)
Total Abbott Shareholders' Investment20,53821,211
 
Noncontrolling Interests in Subsidiaries179115
Total Shareholders' Investment20,71721,326
 
Total Liabilities and Shareholders' Investment52,66641,247
 
External Links 
ABBOTT LABORATORIES (ABT) Fiscal Year 2016
Statements of 10-K in Excel https://www.sec.gov/.../Financial.xlxs
Complete 10-K in HTML https://www.sec.gov/.../10-K.html
Complete 10-K in XBRL https://www.sec.gov/.../10-K-xbrl.zip